PATHOGENETIC JUSTIFICATION AND EFFICIENCY OF MELATONIN APPLICATION IN PATIENTS WITH BRONCHIAL ASTHMA

Abstract. Present study dealt with efficiency of melatonin implementation in a combination therapeutic schedule of bronchial asthma (BA). A group of 248 patients with atopic, or mixed clinical forms of BA being in exacerbation, or medication remission state, and 36 healthy donors were included into...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	G. I. Litvinenko, A. V. Shurlygina, V. S. Shirinsky, V. M. Nepomnjаshih, I. V. Shirinsky, V. A. Trufakin
Formato:	article
Lenguaje:	RU
Publicado:	SPb RAACI 2014
Materias:	melatonin immune status bronchial asthma Immunologic diseases. Allergy RC581-607
Acceso en línea:	https://doaj.org/article/0d2a5554b86e4c9e97ffd35dd4c63c09
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:0d2a5554b86e4c9e97ffd35dd4c63c09
record_format	dspace
spelling	oai:doaj.org-article:0d2a5554b86e4c9e97ffd35dd4c63c092021-11-18T08:03:42ZPATHOGENETIC JUSTIFICATION AND EFFICIENCY OF MELATONIN APPLICATION IN PATIENTS WITH BRONCHIAL ASTHMA1563-06252313-741X10.15789/1563-0625-2012-6-533-540https://doaj.org/article/0d2a5554b86e4c9e97ffd35dd4c63c092014-07-01T00:00:00Zhttps://www.mimmun.ru/mimmun/article/view/613https://doaj.org/toc/1563-0625https://doaj.org/toc/2313-741XAbstract. Present study dealt with efficiency of melatonin implementation in a combination therapeutic schedule of bronchial asthma (BA). A group of 248 patients with atopic, or mixed clinical forms of BA being in exacerbation, or medication remission state, and 36 healthy donors were included into the study. Melatonin (Melaxen, Unifarm, USA) was administered as a single daily dose of 0.003 g, at 21.00, accompanied by a standard therapy in twenty BA patients for 21 days. We determined contents and functional properties of Т- and B-lymphocytes, mononuclear phagocytes, IgE, IL-4, IFNγ levels, as well as melatonin concentrations in blood serum in the morning and evening time. When included into BA treatment protocol, melatonin proved to cause partial restoration of circadian rhythm for Tand B cell subpopulations, mononuclear phagocytes, cytokine production, due to its chronotropic and immunomodulating activity. This effect is associated with a more pronounced clinical effect, thus presuming reversibility of desynchronosis state.G. I. LitvinenkoA. V. ShurlyginaV. S. ShirinskyV. M. NepomnjаshihI. V. ShirinskyV. A. TrufakinSPb RAACIarticlemelatoninimmune statusbronchial asthmaImmunologic diseases. AllergyRC581-607RUMedicinskaâ Immunologiâ, Vol 14, Iss 6, Pp 533-540 (2014)
institution	DOAJ
collection	DOAJ
language	RU
topic	melatonin immune status bronchial asthma Immunologic diseases. Allergy RC581-607
spellingShingle	melatonin immune status bronchial asthma Immunologic diseases. Allergy RC581-607 G. I. Litvinenko A. V. Shurlygina V. S. Shirinsky V. M. Nepomnjаshih I. V. Shirinsky V. A. Trufakin PATHOGENETIC JUSTIFICATION AND EFFICIENCY OF MELATONIN APPLICATION IN PATIENTS WITH BRONCHIAL ASTHMA
description	Abstract. Present study dealt with efficiency of melatonin implementation in a combination therapeutic schedule of bronchial asthma (BA). A group of 248 patients with atopic, or mixed clinical forms of BA being in exacerbation, or medication remission state, and 36 healthy donors were included into the study. Melatonin (Melaxen, Unifarm, USA) was administered as a single daily dose of 0.003 g, at 21.00, accompanied by a standard therapy in twenty BA patients for 21 days. We determined contents and functional properties of Т- and B-lymphocytes, mononuclear phagocytes, IgE, IL-4, IFNγ levels, as well as melatonin concentrations in blood serum in the morning and evening time. When included into BA treatment protocol, melatonin proved to cause partial restoration of circadian rhythm for Tand B cell subpopulations, mononuclear phagocytes, cytokine production, due to its chronotropic and immunomodulating activity. This effect is associated with a more pronounced clinical effect, thus presuming reversibility of desynchronosis state.
format	article
author	G. I. Litvinenko A. V. Shurlygina V. S. Shirinsky V. M. Nepomnjаshih I. V. Shirinsky V. A. Trufakin
author_facet	G. I. Litvinenko A. V. Shurlygina V. S. Shirinsky V. M. Nepomnjаshih I. V. Shirinsky V. A. Trufakin
author_sort	G. I. Litvinenko
title	PATHOGENETIC JUSTIFICATION AND EFFICIENCY OF MELATONIN APPLICATION IN PATIENTS WITH BRONCHIAL ASTHMA
title_short	PATHOGENETIC JUSTIFICATION AND EFFICIENCY OF MELATONIN APPLICATION IN PATIENTS WITH BRONCHIAL ASTHMA
title_full	PATHOGENETIC JUSTIFICATION AND EFFICIENCY OF MELATONIN APPLICATION IN PATIENTS WITH BRONCHIAL ASTHMA
title_fullStr	PATHOGENETIC JUSTIFICATION AND EFFICIENCY OF MELATONIN APPLICATION IN PATIENTS WITH BRONCHIAL ASTHMA
title_full_unstemmed	PATHOGENETIC JUSTIFICATION AND EFFICIENCY OF MELATONIN APPLICATION IN PATIENTS WITH BRONCHIAL ASTHMA
title_sort	pathogenetic justification and efficiency of melatonin application in patients with bronchial asthma
publisher	SPb RAACI
publishDate	2014
url	https://doaj.org/article/0d2a5554b86e4c9e97ffd35dd4c63c09
work_keys_str_mv	AT gilitvinenko pathogeneticjustificationandefficiencyofmelatoninapplicationinpatientswithbronchialasthma AT avshurlygina pathogeneticjustificationandefficiencyofmelatoninapplicationinpatientswithbronchialasthma AT vsshirinsky pathogeneticjustificationandefficiencyofmelatoninapplicationinpatientswithbronchialasthma AT vmnepomnjashih pathogeneticjustificationandefficiencyofmelatoninapplicationinpatientswithbronchialasthma AT ivshirinsky pathogeneticjustificationandefficiencyofmelatoninapplicationinpatientswithbronchialasthma AT vatrufakin pathogeneticjustificationandefficiencyofmelatoninapplicationinpatientswithbronchialasthma
_version_	1718422462184554496

PATHOGENETIC JUSTIFICATION AND EFFICIENCY OF MELATONIN APPLICATION IN PATIENTS WITH BRONCHIAL ASTHMA

Ejemplares similares